Verona Pharma Limited
Records under this name other than the patents Verona Pharma Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 18 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,794,391 | Derivatives of PYRIMIDO[6.1-A]ISOQUINOLIN-4-ONE held by Verona Pharma PLC Term ended Term ended Sep 26, 2021 · High confidence | Term ended | Term ended Sep 26, 2021 | High confidence |
| US 7,105,663 | Derivatives of Pyrimido[6,1-a]isoquinolin-4-one now held by Verona Pharma PLC Term ended Term ended Sep 26, 2021 · High confidence | Term ended | Term ended Sep 26, 2021 | High confidence |
| US 7,378,424 | Derivatives of Pyrimido[6,1-a]isoquinolin-4-one now held by Verona Pharma PLC Term ended Term ended Sep 26, 2021 · High confidence | Term ended | Term ended Sep 26, 2021 | High confidence |
| US 6,991,810 | Product from Starfish held by Verona Pharma PLC, King's College London, National Institute for Biological Standards and Control, Scottish Association for Marine Science Dunstaffnage Marine Laboratory, The University of Liverpool and The University Court of ST. Andrews Lapsed on the fee record Ended Jan 31, 2014 · High confidence | Lapsed on the fee record | Ended Jan 31, 2014 | High confidence |
| 14/342,490 | Treating Cough and Tussive Attacks held by Verona Pharma PLC Abandoned Abandoned Feb 23, 2015 | Abandoned | Abandoned Feb 23, 2015 | |
| 17/280,452 | Pharmaceutical Compositions Comprising RPL554 in HFA-134A for Administration by Inhalation held by Verona Pharma PLC Abandoned Abandoned Apr 5, 2024 | Abandoned | Abandoned Apr 5, 2024 | |
| 17/632,891 | Pharmaceutical Composition Comprising Ensifentrine Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/417,410 | Liquid Pharmaceutical Composition Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/417,864 | Ensifentrine (RPL554) for Treating Moderate Copd Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/616,878 | Pharmaceutical Compositions Comprising RPL554 in HFA-134A for Administration by Inhalation Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |